- Home
- Publications
- Publication Search
- Publication Details
Title
Polo-like kinases and acute leukemia
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-13
DOI
10.1038/s41388-018-0443-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo
- (2018) Ulrike Tontsch-Grunt et al. CANCER LETTERS
- Presenting national HIV/AIDS and sexually transmitted disease research in Brazil
- (2018) Adele Schwartz Benzaken et al. MEDICINE
- PLK4: a link between centriole biogenesis and cancer
- (2017) Radhika Radha Maniswami et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers
- (2017) Stine N. Nielsen et al. PEDIATRIC BLOOD & CANCER
- Plk4 Promotes Cancer Invasion and Metastasis through Arp2/3 Complex Regulation of the Actin Cytoskeleton
- (2016) Karineh Kazazian et al. CANCER RESEARCH
- Polo-like kinase inhibitors in hematologic malignancies
- (2016) Chetasi Talati et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting the mTOR Pathway in Leukemia
- (2016) Shira Dinner et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy
- (2016) Zhenhua Li et al. Journal of Cancer
- Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain
- (2015) Andrej Scharow et al. CHEMBIOCHEM
- Molecular Targeting of the Oncoprotein PLK1 in Pediatric Acute Myeloid Leukemia: RO3280, a Novel PLK1 Inhibitor, Induces Apoptosis in Leukemia Cells
- (2015) Na-Na Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
- (2015) C. Michel Zwaan et al. JOURNAL OF CLINICAL ONCOLOGY
- The deregulated promoter methylation of thePolo-like kinasesas a potential biomarker in hematological malignancies
- (2015) Alejandra Ward et al. LEUKEMIA & LYMPHOMA
- Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines
- (2015) Claudia Münch et al. LEUKEMIA RESEARCH
- Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy
- (2015) Kyung S. Lee et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1
- (2014) Sung Min Kim et al. AMINO ACIDS
- Declining childhood and adolescent cancer mortality: Great progress but still much to be done
- (2014) Kathy Pritchard-Jones et al. CANCER
- Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia
- (2014) Antonino Maria Spartà et al. CELL CYCLE
- Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance
- (2014) Mihaela Marina Frontiers in Bioscience-Landmark
- Aging and Risk of Severe, Disabling, Life-Threatening, and Fatal Events in the Childhood Cancer Survivor Study
- (2014) Gregory T. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
- (2014) B T Gjertsen et al. LEUKEMIA
- Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications
- (2014) Bryan R Meade et al. NATURE BIOTECHNOLOGY
- The Childhood Leukemia International Consortium
- (2013) Catherine Metayer et al. Cancer Epidemiology
- Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain
- (2013) G. Osca-Gelis et al. HAEMATOLOGICA
- TrkC promotes survival and growth of leukemia cells through Akt-mTOR-Dependent Up-Regulation of PLK-1 and Twist-1
- (2013) Min Soo Kim et al. MOLECULES AND CELLS
- Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program
- (2013) Richard Gorlick et al. PEDIATRIC BLOOD & CANCER
- The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia
- (2013) Alessia Casolaro et al. PLoS One
- Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series
- (2012) R. Fruscio et al. ANNALS OF ONCOLOGY
- A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
- (2012) K Mross et al. BRITISH JOURNAL OF CANCER
- PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo
- (2012) G. Dasmahapatra et al. CLINICAL CANCER RESEARCH
- Polo-like kinase-1 regulates kinetochore–microtubule dynamics and spindle checkpoint silencing
- (2012) Dan Liu et al. JOURNAL OF CELL BIOLOGY
- Plk1 negatively regulates PRC1 to prevent premature midzone formation before cytokinesis
- (2012) Chi-Kuo Hu et al. MOLECULAR BIOLOGY OF THE CELL
- NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies
- (2012) B. Valsasina et al. MOLECULAR CANCER THERAPEUTICS
- Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions
- (2011) Leonidas Benetatos et al. ANNALS OF HEMATOLOGY
- An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies
- (2011) Kristina Spaniol et al. ANTI-CANCER DRUGS
- Plk2 regulated centriole duplication is dependent on its localization to the centrosome and a functional polo-box domain
- (2011) Onur Cizmecioglu et al. CELL CYCLE
- From Plk1 to Plk5
- (2011) Guillermo de Cárcer et al. CELL CYCLE
- Modern Therapy of Acute Lymphoblastic Leukemia
- (2011) Renato Bassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Plk5, a Polo Box Domain-Only Protein with Specific Roles in Neuron Differentiation and Glioblastoma Suppression
- (2011) G. de Carcer et al. MOLECULAR AND CELLULAR BIOLOGY
- Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells
- (2011) Monika Raab et al. Nature Communications
- The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation
- (2009) Li Li et al. ACTA PHARMACOLOGICA SINICA
- Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells
- (2009) A. G. Renner et al. BLOOD
- Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response
- (2009) Emeline de Viron et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Pan-Specific Inhibitor of the Polo-Box Domains of Polo-like Kinases Arrests Cancer Cells in Mitosis
- (2009) Wolfgang Reindl et al. CHEMBIOCHEM
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
- Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation
- (2009) Meixiang Sang et al. GENES TO CELLS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started